Table 1.
Total | Women | Men | Age tertile 1: | Age tertile 2: | Age tertile 3: | |
---|---|---|---|---|---|---|
(n = 2916) | (n = 804) | (n = 1934) | 20–69 years | 70–81 years | ≥ 82 years | |
(n = 999) | (n = 988) | (n = 929) | ||||
Sex | ||||||
Female | 804 (27.6%) | n/a | n/a | 204 (20.4%) | 262 (26.5%) | 338 (36.4%) |
Male | 1934 (66.3%) | n/a | n/a | 725 (72.6%) | 668 (67.6%) | 541 (58.2%) |
Unknown | 178 (6.1%) | n/a | n/a | 70 (7.0%) | 58 (5.9%) | 50 (5.4%) |
Age, years | 73.0 (12.7) | 75.6 (13.3) | 72.3 (12.4) | n/a | n/a | n/a |
18–50 years | 160 (5.5%) | 45 (5.6%) | 96 (5.0%) | n/a | n/a | n/a |
51–60 years | 330 (11.3%) | 63 (7.8%) | 244 (12.6%) | n/a | n/a | n/a |
61–70 years | 579 (19.9%) | 117 (14.6%) | 432 (22.3%) | n/a | n/a | n/a |
71–80 years | 806 (27.6%) | 214 (26.6%) | 548 (28.3%) | n/a | n/a | n/a |
81–90 years | 933 (32.0%) | 311 (38.7%) | 568 (29.4%) | n/a | n/a | n/a |
> 90 years | 108 (3.7%) | 54 (6.7%) | 46 (2.4%) | n/a | n/a | n/a |
Tertile 1: 20–69 years | 999 (34.3%) | 204 (25.4%) | 725 (37.5%) | n/a | n/a | n/a |
Tertile 2: 70–81 years | 988 (33.9%) | 262 (32.6%) | 668 (34.5%) | n/a | n/a | n/a |
Tertile 3: ≥ 82 years | 929 (31.9%) | 338 (42.0%) | 541 (28.0%) | n/a | n/a | n/a |
HF co-medicationa | ||||||
BB | 2207 (75.7%) | 614 (76.4%) | 1458 (75.4%) | 738 (73.9%) | 794 (80.4%) | 675 (72.7%) |
ACEi | 468 (16.0%) | 153 (19.0%) | 285 (14.7%) | 119 (11.9%) | 161 (16.3%) | 188 (20.2%) |
ARB | 357 (12.2%) | 136 (16.9%) | 194 (10.0%) | 86 (8.6%) | 125 (12.7%) | 146 (15.7%) |
ARNi | 1541 (52.8%) | 341 (42.4%) | 1113 (57.5%) | 611 (61.2%) | 558 (56.5%) | 372 (40.0%) |
Any RASi | 2174 (74.6%) | 572 (71.1%) | 1469 (76.0%) | 756 (75.7%) | 765 (77.4%) | 653 (70.3%) |
MRA | 1519 (52.1%) | 360 (44.8%) | 1064 (55.0%) | 604 (60.5%) | 542 (54.9%) | 373 (40.2%) |
SGLT2i | 1479 (50.7%) | 328 (40.8%) | 1065 (55.1%) | 576 (57.7%) | 557 (56.4%) | 346 (37.2%) |
Diuretic | 2244 (77.0%) | 635 (79.0%) | 1487 (76.9%) | 684 (68.5%) | 786 (79.6%) | 774 (83.3%) |
Digitalis | 290 (9.9%) | 98 (12.2%) | 182 (9.4%) | 75 (7.5%) | 107 (10.8%) | 108 (11.6%) |
Ivabradine | 148 (5.1%) | 41 (5.1%) | 99 (5.1%) | 100 (10.0%) | 38 (3.8%) | 10 (1.1%) |
HF drug combinations | ||||||
≤ 1 drug class | 616 (21.1%) | 205 (25.5%) | 370 (19.1%) | 205 (20.5%) | 160 (16.2%) | 251 (27.0%) |
2 drug classes | 752 (25.8%) | 235 (29.2%) | 480 (24.8%) | 184 (18.4%) | 251 (25.4%) | 317 (34.1%) |
3 drug classes | 745 (25.5%) | 200 (24.9%) | 498 (25.7%) | 247 (24.7%) | 272 (27.5%) | 226 (24.3%) |
4 drug classes | 803 (27.5%) | 164 (20.4%) | 586 (30.3%) | 363 (36.3%) | 305 (30.9%) | 135 (14.5%) |
Non-HF co-medication | ||||||
Oral anticoagulant | 1661 (57.0%) | 456 (56.7%) | 1116 (57.7%) | 429 (42.9%) | 618 (62.6%) | 614 (66.1%) |
Antiplatelet medication | 760 (26.1%) | 168 (20.9%) | 540 (27.9%) | 282 (28.2%) | 282 (28.5%) | 196 (21.1%) |
Lipid-lowering medication | 1726 (59.2%) | 395 (49.1%) | 1226 (63.4%) | 563 (56.4%) | 661 (66.9%) | 502 (54.0%) |
Glucose-lowering medication | 814 (27.9%) | 207 (25.7%) | 566 (29.3%) | 252 (25.2%) | 334 (33.8%) | 228 (24.5%) |
Anti-depressants | 365 (12.5%) | 137 (17.0%) | 206 (10.7%) | 121 (12.1%) | 122 (12.3%) | 122 (13.1%) |
NSAIDs | 329 (11.3%) | 78 (9.7%) | 232 (12.0%) | 124 (12.4%) | 104 (10.5%) | 101 (10.9%) |
Antiobstructive medication | 682 (23.4%) | 164 (20.4%) | 481 (24.9%) | 215 (21.5%) | 268 (27.1%) | 199 (21.4%) |
Gout medication | 791 (27.1%) | 149 (18.5%) | 597 (30.9%) | 220 (22.0%) | 306 (31.0%) | 265 (28.5%) |
Data are n (%) or mean (SD)
HF heart failure, BB beta-blockers, MRA mineralocorticoid receptor antagonists, RASi renin–angiotensin system inhibitors, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, ARNi angiotensin receptor–neprilysin inhibitor [ARNi]), SGLT2i sodium-glucose co-transporter-2 inhibitors, NSAIDs non-steroidal anti-inflammatory drug, n/a not available
aUse of co-medication was assessed during the three months prior to vericiguat initiation